Walsh Deina H 4

What Happened

• Deina H. Walsh, Chief Financial Officer of Bone Biologics Corp (BBLG), received a grant/award of 8,335 derivative units reported as acquired on 2026-01-08. The filing shows an acquisition price of $0.00 for these derivative securities. The award was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan and, per the filing, is fully vested and immediately exercisable.

Key Details

• Transaction date: 2026-01-08 (reported on Form 4 filed 2026-01-21).
• Transaction type/code: A (Grant/Award — derivative).
• Quantity and price: 8,335 units @ $0.00 (reported as derivative securities).
• Vesting/exercisability: Footnote states grant vests and becomes exercisable immediately; filing notes the option is fully vested as of the report date.
• Shares owned after transaction: Not specified in the information provided in this summary.
• Timeliness: The Form 4 was filed 13 days after the transaction date (filed Jan 21 for Jan 8 transaction), later than the typical 2-business-day deadline for insiders.

Context

• This was a derivative award (an option grant per the filing footnote). No shares were reported sold or purchased in the transaction — the filing documents an award of an option-type security that is fully vested and exercisable immediately. Converting these derivative units into actual shares would require exercise according to the award terms.